The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market, with small molecules achieving 5–10% approval rates over 15–20 years. In oncology, success rates fall to just 3%. But antisense oligonucleotides (ASOs) are beginning to rewrite those odds through rational design, according to a recent analysis.
ASOs are short synthetic strands of DNA or RNA that silence disease-causing genes. With six new FDA approvals since 2023 and more than 50 candidates in active trials, the technology is experiencing a long-anticipated breakout. Industry data shows that ASOs are shifting approval odds, offering a faster path from discovery to patient access.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) aims to be at the forefront with OT-101 (Trabedersen), the only TGF-β2-specific antisense therapy in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The company's candidate represents a new wave of rationally designed ASOs that could further improve success rates.
The regulatory momentum is evident: total ASO approvals have now surpassed 20, with the pace accelerating. This trend suggests that ASOs may overcome the development bottlenecks that have plagued small molecules, particularly in oncology where targeted therapies are urgently needed.
For more information on OTLC, visit the company's newsroom at ibn.fm/OTLC.
BioMedWire (BMW) is a specialized communications platform covering biotechnology, biomedical sciences, and life sciences. It is part of the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. Learn more at BioMedWire.com.
Full terms of use and disclaimers are available at BioMedWire.com/Disclaimer.
